News
-
-
PRESS RELEASE
Immunic, Inc. Reports Third Quarter 2024 Financial Results and Provides Corporate Update
Immunic, Inc. reports Q3 2024 financial results, positive Phase 3 ENSURE Program interim analysis. Twin Phase 3 ENSURE trials and Phase 2 CALLIPER trial on track. Webcast held on Nov 7. IMUX stock update -
-
PRESS RELEASE
Immunic, Inc. to Announce Financial Results for the Third Quarter Ended September 30, 2024, and Provide Corporate Update
Immunic, Inc. (Nasdaq: IMUX) to release Q3 financial results and corporate update on Nov 7, 2024. Webcast at 8:00 am ET. Company developing therapies for inflammatory and autoimmune diseases. Visit www.imux.com for more info -
-
PRESS RELEASE
Immunic to Participate in Industry, Scientific and Investor Conferences in November
Immunic to participate in industry, scientific, and investor conferences in November 2024, presenting data on IMU-856 for celiac disease. Details on events and presentations available on company website -
-
PRESS RELEASE
Immunic Announces Positive Outcome of Interim Analysis of Phase 3 ENSURE Program of Vidofludimus Calcium in Relapsing Multiple Sclerosis
Immunic announces positive outcome of interim analysis of Phase 3 ENSURE Program for vidofludimus calcium in RMS. Trials recommended to continue unchanged till 2026 -
-
PRESS RELEASE
Immunic Presents Key Vidofludimus Calcium Data at the 40th Congress of ECTRIMS, Highlighting Its Therapeutic Potential in Multiple Sclerosis
Immunic presents key Vidofludimus Calcium data at the 40th Congress of ECTRIMS, highlighting its therapeutic potential in Multiple Sclerosis. Immunic, Inc. (Nasdaq: IMUX) showcases findings at the conference in Copenhagen, Denmark